Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. and set a lead plaintiff deadline of August 10, 2026 for investors who suffered substantial losses. The lawsuit covers a class period from August 9, 2024 through March 25, 2026 and alleges that the company artificially inflated its stock price by misrepresenting its financial condition, revenue recognition, and business practices. Specifically, the complaint claims ADMA engaged in an undisclosed related party transaction, used channel stuffing to create the appearance of revenue, and lacked adequate internal controls. The alleged misconduct was revealed through a series of corrective events, including a Culper Research short-seller report on March 24, 2026 that triggered a combined two-day stock decline of 31.6 percent, followed by a further 13.9 percent drop on March 26 after the company responded and Cantor Fitzgerald downgraded the stock. Investors with significant losses are encouraged to contact the firm before the August 10 deadline to seek lead plaintiff status.
ADMA Biologics IncSecurities fraud class action lawsuit alleges misrepresentation, channel stuffing, and lack of internal controls, leading to stock decline.
ServiceNow Inc